ReviewCurrent cardiology reviews2015
Genetics and heart failure: a concise guide for the clinician.
Review in Current cardiology reviews, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03548779 (North Carolina Genomic Evaluation by Next-generation Exome Sequencing, 2), which is not on this map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
North Carolina Genomic Evaluation by Next-generation Exome Sequencing, 2
Who cites it
27 citing papers in PubMed, 53 citations in OpenAlex.
- Polygenic prediction of cardiorespiratory fitness in the Trøndelag health study (HUNT).Scientific reports · 2025Article
- Review
- Review
- Review
- Mendelian randomization of plasma lipidome, inflammatory proteome and heart failure.ESC heart failure · 2024Article
- Knockdown of SCN5A alters metabolic-associated genes and aggravates hypertrophy in the cardiomyoblast.Molecular biology reports · 2024Article
- The Role of Genetics in the Management of Heart Failure Patients.International journal of molecular sciences · 2023Review
- Allostatic load and incident heart failure in the Reasons for Geographic and Racial Differences in Stroke (REGARDS) study.BMC cardiovascular disorders · 2023Article
- Genetic predisposition study of heart failure and its association with cardiomyopathy.The Egyptian heart journal : (EHJ) : official bulletin of the Egyptian Society of Cardiology · 2022Review
- RNA-seq driven expression and enrichment analysis to investigate CVD genes with associated phenotypes among high-risk heart failure patients.Human genomics · 2021Article
- Interactions Networks for Primary Heart Sarcomas.Cancers · 2021Article
- Clinical impact of echocardiography parameters and molecular biomarkers in heart failure: Correlation ofExperimental and therapeutic medicine · 2021Article
- Elevated plasma fatty acid-binding protein 3 is related to prolonged corrected QT interval and reduced ejection fraction in patients with stable angina.International journal of medical sciences · 2021Observational
- Human iPSCs and Genome Editing Technologies for Precision Cardiovascular Tissue Engineering.Frontiers in cell and developmental biology · 2021Review
- Evidence of Clonal Hematopoiesis and Risk of Heart Failure.Current heart failure reports · 2020Review
- Coexisting Morbidities in Heart Failure: No Robust Interaction with the Left Ventricular Ejection Fraction.Current heart failure reports · 2020Review
- An overview of heart failure in low- and middle-income countries.Cardiovascular diagnosis and therapy · 2020Review
- Predictors of Mortality in Patients with Chronic Heart Failure: Is Hyponatremia a Useful Clinical Biomarker?International journal of general medicine · 2020Article
- Update on heart failure management and future directions.The Korean journal of internal medicine · 2019Review
- Semantic Multi-Classifier Systems Identify Predictive Processes in Heart Failure Models across Species.Biomolecules · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
The pathogenesis of heart failure involves a complex interaction between genetic and environmental factors. Genetic factors may influence the susceptibility to the underlying etiology of heart failure, the rapidity of disease progression, or the response to pharmacologic therapy. The genetic contribution to heart failure is relatively minor in most multifactorial cases, but more direct and profound in the case of familial dilated cardiomyopathy. Early studies of genetic risk for heart failure focused on polymorphisms in genes integral to the adrenergic and renin-angiotensin-aldosterone system. Some of these variants were found to increase the risk of developing heart failure, and others appeared to affect the therapeutic response to neurohormonal antagonists. Regardless, each variant individually confers a relatively modest increase in risk and likely requires complex interaction with other variants and the environment for heart failure to develop. Dilated cardiomyopathy frequently leads to heart failure, and a genetic etiology increasingly has been recognized in cases previously considered to be "idiopathic". Up to 50% of dilated cardiomyopathy cases without other cause likely are due to a heritable genetic mutation. Such mutations typically are found in genes encoding sarcomeric proteins and are inherited in an autosomal dominant fashion. In recent years, rapid advances in sequencing technology have improved our ability to diagnose familial dilated cardiomyopathy and those diagnostic tests are available widely. Optimal care for the expanding population of patients with heritable heart failure involves counselors and physicians with specialized training in genetics, but numerous online genetics resources are available to practicing clinicians.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.